These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31936488)

  • 21. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy.
    Cong L; Xia ZK; Yang RY
    Arch Pharm (Weinheim); 2014 Sep; 347(9):609-15. PubMed ID: 24917246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.
    Schlütke L; Immer M; Preu L; Totzke F; Schächtele C; Kubbutat MHG; Kunick C
    Eur J Pharm Biopharm; 2018 May; 126():89-94. PubMed ID: 28315448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
    Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
    J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors.
    Kong X; Pan P; Li D; Tian S; Li Y; Hou T
    Phys Chem Chem Phys; 2015 Feb; 17(8):6098-113. PubMed ID: 25644934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
    Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
    J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
    Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
    J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies.
    Zhang W; Qiu KX; Yu F; Xie XG; Zhang SQ; Chen YJ; Xie HD
    Comput Biol Chem; 2017 Oct; 70():186-190. PubMed ID: 28892749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
    Alshareef A; Zhang HF; Huang YH; Wu C; Zhang JD; Wang P; El-Sehemy A; Fares M; Lai R
    Sci Rep; 2016 Sep; 6():33710. PubMed ID: 27641368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
    James N; Ramanathan K
    Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives.
    Nossier ES; Abd El-Karim SS; Khalifa NM; El-Sayed AS; Hassan ESI; El-Hallouty SM
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30477238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.
    Peddi SR; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2016 Oct; 36(5):488-504. PubMed ID: 26758803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
    Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
    J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.